

Targeting DNA Repair Mechanisms with Spironolactone to Enhance LP-184 CNS Pharmacodynamics and Efficacy


Bachchu Lal¹, Aditya Kulkarni², Marc Chamberlain², Karisa Schreck³, Hernando Lopez-Bertoni^{1,3}, Kishor Bhatia², John Latterra^{1,3}

¹The Kennedy Krieger Institute, Baltimore MD 21205, ²Lantern Pharma, Dallas TX 75201, ³Johns Hopkins School of Medicine, Baltimore, MD 21287

Abstract

Limited CNS bioavailability and on-target pharmacodynamics are major obstacles to developing new and effective systemic therapies for GBM and other primary brain tumors. Strategies to overcome these obstacles include blood-brain barrier disruption to enhance CNS penetration and brain penetrant drug combinations that enhance tumor cell chemosensitivity through synthetic lethality. LP-184 is a synthetic acylfulvene class small molecule alkylator that induces DNA damage and inhibits MGMT-expressing GBM cell viability with IC₅₀ range ~20-300 nM. LP-184 improves survival in orthotopic GBM xenograft models with pre-clinical brain C_{max} ~840 nM and brain tumor C_{max} ~2,500 nM. Pre-clinical brain/plasma and brain tumor plasma ratios are 0.11 and 0.2, respectively. Pharmacokinetics from a first-in-human Phase 1a study (NCT05933265) shows plasma C_{max} ~1000 nM at likely the RDE, predicting >IC₅₀-range of brain and tumor concentrations based on in vitro and in vivo pre-clinical data. Transcription-coupled nucleotide excision repair (TC-NER) reverses LP-184 DNA damage and unbiased GSEA coupled with LP-184 sensitivity screens identified ERCC3, a TC-NER complex helicase, as a target for sensitizing GBM cells to LP-184. Spironolactone, an FDA-approved BBB-permeable aldosterone inhibitor, is predicted to sensitize GBM to LP-184 via multiple molecular targets. Treating GBM models including PDX-derived cells with spironolactone (25 µM) induces ERCC3 protein degradation by up to 95% and sensitizes cells to LP-184 in vitro (~5-fold IC₅₀ reduction). Kinetic analysis of spironolactone-induced (35 mg/kg daily) ERCC3 degradation in orthotopic GBM PDX xenografts revealed ~50%, 56% and 79% degradation on treatment days -2, -1, and 0, respectively. Furthermore, spironolactone enhances orthotopic GBM PDX responses to LP-184. Machine learning approaches also associate spironolactone-induced GBM cell sensitization to LP-184 with down-regulation of the TC-NER complex endonuclease ercc1 and the DNA damage sensor ctn2. These findings provide a rationale and framework for a planned Phase 1b/2a trial to evaluate LP-184 + spironolactone therapy against recurrent GBM.

LP-184: Mechanism of Action



GBM with higher PTGR1 levels compared to normal brain sufficient to activate LP-184

PTGR1 expression level in GBM	Number of patients	Log2 (normalized RNAseq as transcripts per million + 1) range	Percentage
Low	0	0	0%
Intermediate	148	6.31 - 9.71	89.16%
High	18	9.76 to 10.61	10.84%

Normal brain (GTxe data) mean **3.67 (range 0-6.06)**

Glioblastoma (TCGA data) mean **4.98 (1.3x higher)**

Alkylator Chemotherapy Comparison


	LP-184	Temozolomide	Nitrosourea (CCNU)
Molecular weight (kD)	304	194	233
DNA repair system	TC-NER & HR	MGMT	HR
Tumor/blood concentration ratio	0.2	0.2	0.5
IC ₅₀	200nM	500 mM	50 mM
Bioactivation	Prodrug, conversion by intracellular PTGR1	Prodrug, spontaneous conversion by hydrolysis to MTIC	Prodrug, spontaneous conversion by hydrolysis

Preclinical Results

In silico comparison of LP-184 anti-tumor activity versus expression of PTGR1

In silico LP-184 sensitivity correlates with low TC-NER & high EGFR signaling pathway

EGFR altered GBM cell lines show enhanced sensitivity to LP-184



LP-184 penetrates the blood brain barrier (BBB) with favorable CNS tumor bioavailability


Matrix	LP-184 4 mg/kg single i.v. dose pharmacokinetic data (Mean ± SEM)						LP-184 Brain Tissue / Plasma Ratio	Historical TMZ Brain Tissue / Plasma Ratio
	C _{max} (ng/g or ng/mL)	T _{max} (h)	AUC ₀₋₂₄ (ng.h/g or ng.h/mL)	Half-Life (h)	C _{max} (nM)	AUC (nM)		
Plasma	3438 ± 125	0.0833	1592 ± 48.7	0.236	11296 ± 410	5231 ± 160	-	-
Peritumoral Brain	279 ± 20.2	0.250	165 ± 11.6	0.383	916 ± 66	542 ± 38	0.103	0.118
Contralateral Brain	223 ± 50.6	0.250	123 ± 15.9	0.444	732 ± 166	404 ± 52	0.077 ± 0.12	-
Brain Tumor	773 ± 58.6	0.0833	319 ± 36.4	0.281	2539 ± 193	1048 ± 120	0.200	0.202

- LP-184 pharmacokinetic analyses in SCID mice bearing orthotopic GBM xenografts showed normal brain/plasma ratio 0.1 (C_{max} = 916 nM) and brain tumor/plasma ratio 0.2 (C_{max} = 2539 nM).
- LP-184 BBB permeability is comparable to TMZ and brain tumor C_{max} achieved after a single i.v. infusion is greater than mean LP-184 IC₅₀ (~200 nM) for sensitive GBM cell models.


Preclinical Results

Combination with Spironolactone enhances the in vitro and in vivo anti-tumor efficacy of LP-184


A 3-6 fold increase in LP-184 sensitivity




B 3 fold increase in γH2AX DNA damage response to LP-184



C 24h SP treatment depleted ERCC3 protein by up to 95%




D Combination treatment of LP-184 and Spironolactone in vivo induced complete tumor regression with prolonged duration of response in orthotopic M1123 mesenchymal GBM




- Spironolactone treatment leads to depletion of ERCC3 protein and up to 6x increased sensitivity to LP-184 treatment
- Spironolactone monotherapy had no effect on tumor growth compared with vehicle-treated
- LP-184 alone and combined with Spironolactone induced complete or near complete tumor regression.
- Combining Spironolactone with LP-184 generated more durable responses

ERCC3 levels nadir 8 hours post Spironolactone administration in Mayo39 GBM xenografts



Clinical Results

LP-184 Phase 1a Study - Pharmacokinetic C_{max} and AUC versus Dose Level



Conclusion

- LP-184 is a novel potent brain penetrant alkylator
- Bioactivation occurs intracellularly by the enzyme PTGR1
- Alkylation by LP-184 is repaired by NER which can be pharmacologically inhibited by predose spironolactone resulting in increased sensitivity to LP-184
- FIH PK data suggest that LP is likely to achieve sufficient clinical CNS bioavailability (200 nM) well above in vitro IC₅₀ (~50 nM) when combined with SP

Reference

- Stokes MD, Kishor Bhatia A, McMorris TC, Estes LA, Reiner MJ. Hydroxyurea derivatives of irinotecan with improved antitumor efficacy. *Bioorg Med Chem Lett*. 2016;26(7):1836-1838. doi:10.1016/j.bmcl.2016.02.028
- Tanssaa M, Saurio S. Chemistry and biology of acylfulvenes: sesquiterpene-derived antitumor agents. *Chem Rev*. 2012;112(6):3578-3610. doi:10.1021/cr2001367
- Yu X, Erzinger MM, Pletsch KE, et al. Up-regulation of human prostaglandin synthase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent. *J Pharmacol Exp Ther*. 2012; 340(2):406-413. doi:10.1124/jpet.111.191111
- Gong J, Vaidyanathan VG, Yu X, Kessler TW, Peterson LA, Saurio S. Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent. *J Am Chem Soc*. 2007;129(21):6710-6711. doi:10.1021/ja069991t
- Neek JF, Gong J, Yu X, Saurio S. Quantitative correlation of drug bioactivation and deoxyadenosine alkylation by acylfulvene. *Chem Res Toxicol*. 2007;20(10):1513-1519. doi:10.1021/tx700175e
- Edrine G, Fabbri E, Lo Nigro C, Decechi MC, Gambini R. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). *Int J Oncol*. 2015; 47(2):417-426.
- Chaudhary AK, Li P, Sun Y, Wang Q, Zhu Q, Wang AA. Spironolactone-induced NER degradation requires TRIM18 integrity and ubiquitin-selective protease VCP/p97. *Cell Cycle*. 2021; 20(1):81-95.
- Lee B, Kulkarni A, McDermott J, Wu R, Wu Y, et al. Latterra J (2023) Preclinical Efficacy of LP-184 in Tumor-Site Activated Synthetic Enzyme Therapeutic in Glioblastoma. *Clinical Cancer Research*. 29(20):4209-4218.
- Phu M, Wu, Deng A, Grossman S. A., & Bielecky J. Q. (2011). Tissue concentration of systemically administered antineoplastic agents in human brain tumors. *Journal of neuro-oncology*, 104(3), 629-638. doi:10.1007/s11068-010-9268-8

Connect with us

Lantern Pharma.



starlight therapeutics

